As per the National Institute of Health 2018 report, the incidence of MPS II is 1 in 100,000 to 1 in 160,000 in males. People with severe cases start to lose basic functional skills between the ages of 6 and 8. The market is increasing in the forecast year 2023-2030 because of several reasons, such as the increasing number of players in the market and the growing adoption of gene therapy. Because of increasing demand, several manufacturers focus on producing gene therapies and are achieving product approval and marketing authorizations.
Access Full Report @ https://www.databridgemarketresearch.com/jp/reports/global-hunter-syndrome-treatment-market
Data Bridge Market Research analyses that the Global Hunter Syndrome Treatment Market is expected to reach the value of USD 1794.67 million by 2030 from USD 927.57 million in 2022 at a CAGR of 8.6% during the forecast period. The increasing demand for the hunter syndrome treatment will provide potential opportunities for the market growth in the forecast period.
Increasing demand of gene therapy is anticipated to drive the market's growth rate
Gene therapy is considered to be an effective treatment for MPS II and has led to increasing adoption and demand day by day for novel and long-lasting results. Manufacturers are primarily focused on producing gene therapies and are achieving product approval and marketing authorizations because of the rising demand. Presently, several companies are highly engaged in offering gene therapy services to patients with MPS II. For instance, gene therapy provided by Homology Medicines Inc. is mainly based on the approach that uses AAVHSC vectors to deliver a functional gene to a cell where there is a missing or mutated gene. Once paid, the functional gene may lead to therapeutic protein expression. With gene therapy, the genes do not mix into the genome; hence this approach can be curative in slow- or non-dividing cells, such as CNS or adult liver.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Severity (Mild to Moderate, Moderate to Severe), Type (Enzyme Replacement Therapy (ERT), Stem Cell Transplant, Surgical Treatment, Others), Complications (Respiratory Disorders, Neurological Disorders, Gastrointestinal Disorders, Cardiovascular, Ophthalmic, Audiologic, Dental, Musculoskeletal, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Takeda Pharmaceutical Company Limited (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.), Medtronic (Ireland.), Abbott (U.S.), BD (U.S.), Johnson & Johnson Services, Inc., GSK Plc. (U.K.), Bayer AG (Germany), Zimmer Biomet (U.S.), Stryker Corporation (U.S.), Homology Medicines, Inc (U.S.), Novartis AG (Switzerland), Pfizer Inc.(U.S.), JCR Pharmaceuticals Co., Ltd.(Japan), Sangamo Therapeutics (U.S.), AVROBIO, Inc (U.S.), REGENXBIO Inc (U.S), CANbridge Life Sciences Ltd.(Taiwan)., Denali Therapeutics (U.S.), and Jasper Therapeutics, Inc. (U.S.)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
Global hunter syndrome treatment market is categorized into five notable segments which are based on severity, type, complications, end-user and distribution channel.
- On the basis of severity, the global hunter syndrome treatment market is segmented into mild to moderate and moderate to severe
The moderate to severe segment of severity type is anticipated to dominate the hunter syndrome treatment market
The moderate to severe segment is expected to dominate the market with the market share of 62.22% due to rise in the cases of incidence rate of genetic inherited disorders among population globally.
- On the basis of type, the global hunter syndrome treatment market is segmented into enzyme replacement therapy (ERT), stem cell transplant, surgical treatment and others.
The enzyme replacement therapy (ERT) segment of type is anticipated to dominate the hunter syndrome treatment market
The enzyme replacement therapy (ERT) segment is expected to dominate the market with the market share of 90.88% due to increasing adoption of gene therapy in the market.
- On the basis of complications, the global hunter syndrome treatment market is segmented into respiratory disorders, neurological disorders, gastrointestinal disorders, cardiovascular, ophthalmic, audiologic, dental, musculoskeletal and others. The respiratory disorders segment is expected to dominate the global hunter syndrome treatment market with the market share of 20.43% due to growing R&D investments by major market players in the market.
- On the basis of end-user, the global hunter syndrome treatment market is segmented into hospitals, clinics, home healthcare and others. The hospitals segment is expected to dominate the market with the market share of 47.50% because of favourable government initiatives in the market.
- On the basis of distribution channel, the global hunter syndrome treatment market is segmented into hospital pharmacy, retail pharmacy, online pharmacy and others. The hospital pharmacy segment is expected to dominate the market with the market share of 80.23% due to novel product launches and approvals in the market.
Major Players
Data Bridge Market Research recognizes the following companies as the major hunter syndrome treatment market players in hunter syndrome treatment market are Teladoc Health, Inc. (U.S.), Siemens (Germany), Cisco Systems, Inc. (U.S.), Koninklijke Philips N.V. (Netherlands), IBM (U.S.), Cerner Corporation (U.S.),, Medtronic (Ireland), F. Hoffmann-La Roche Ltd (Switzerland), Tunstall Group (United Kingdom), American Well (U.S.), CareCloud, Inc. (U.S.), eClinicalWorks (U.S.) , AMD Global Telemedicine (U.S.).
Market Development
- In 2021, GC Pharma and Clinigen K.K. received Japanese manufacturing and marketing approval for Hunterase ICV (intracerebroventricular) Injection 15 mg for treating patients for mucopolysaccharidosis type II (Hunter syndrome)
- In 2020, CANbridge Pharmaceuticals Inc. announced that it received marketing approval from China's National Medical Products Administration (NMPA) for Hunterase (Idursulfase beta Injection), which is an enzyme replacement therapy (ERT) for the long-term treatment of patients with mucopolysaccharidosis II.
Regional Analysis
Geographically, the countries covered in the hunter syndrome treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
As per Data Bridge Market Research analysis:
North America is the dominant region in hunter syndrome treatment market during the forecast period 2022 to 2029
North America dominates the hunter syndrome treatment market due to the growing investment in innovative R&D for novel drug products. Also, the rising incidence of genetic inherited disorders and increasing adoption of gene therapy is also helping in the growth of the market.
Asia-Pacific is estimated to be the fastest-growing region in hunter syndrome treatment market the forecast period 2022 to 2029
Asia-Pacific is expected to grow during the forecast period of 2023 to 2030 because of the development of healthcare infrastructure and the increasing number of generic drug manufacturer in this region. In addition to this, growing investment in innovative R&D for novel treatment product are anticipated to boost the market's growth rate in this region.
For more detailed information about hunter syndrome treatment market report, click here – https://www.databridgemarketresearch.com/jp/reports/global-hunter-syndrome-treatment-market
